Literature DB >> 3481271

Simple, rapid, quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody.

P L Nara1, W C Hatch, N M Dunlop, W G Robey, L O Arthur, M A Gonda, P J Fischinger.   

Abstract

A simple, rapid, quantitative syncytium-forming microassay for the detection of human immunodeficiency virus (HIV-I) isolates is described. A virus-syncytial sensitive clone of CEM cells (CEM-SS) was identified and made adherent to flat bottom 96-well microtiter dishes. Following the addition of virus, these cells develop easily quantifiable, adherent syncytia on a background of confluent, normal CEM-SS monolayer in 4 to 6 days. One-hit kinetics for syncytia formation were obtained at various multiplicities of infection. Syncytia are associated with complete virion production and cytoplasmic localization of the p24 core protein (detected by immunofluorescence). Total infectious virus can be accurately determined in this assay; these results showed a close correlation with p24 and gp120 induction when microtiter well supernatants were passed to fresh cells and evaluated by competitive radioimmunoassay. Studies of p24 antigen induction at and beyond the end point of syncytia formation indicate that there are no detectable nonsyncytial variants in standard HIV-I stocks. Six divergent HIV-I isolates (HTLV-IIIB, -RFII, -MN, -RUTZ, -CC, and LAV-1), as well as HTLV-IIIB and LAV-1 reisolated from persistently infected chimpanzees, produce quantifiable syncytia which vary slightly in their developmental morphology. Accurate neutralization titers are readily obtained from easily constructed multiplicity curves derived from serial dilutions of test sera. Inherent within this system is a flexible method for studying various kinetics of antibody/virus interactions, as well as blocking and interference studies with any candidate antiviral compounds.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3481271     DOI: 10.1089/aid.1987.3.283

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  95 in total

1.  Colorectal delivery and retention of PEG-Amprenavir-Bac7 nanoconjugates--proof of concept for HIV mucosal pre-exposure prophylaxis.

Authors:  Mahta Samizadeh; Xiaoping Zhang; Simi Gunaseelan; Antoinette G Nelson; Matthew S Palombo; Daniel R Myers; Yashveer Singh; Usha Ganapathi; Zoltan Szekely; Patrick J Sinko
Journal:  Drug Deliv Transl Res       Date:  2016-02       Impact factor: 4.617

2.  Early growth response-1 is required for CD154 transcription.

Authors:  Randy Q Cron; Rupa Bandyopadhyay; Anna Genin; Michael Brunner; Gilbert J Kersh; Jiyi Yin; Terri H Finkel; Mary K Crow
Journal:  J Immunol       Date:  2006-01-15       Impact factor: 5.422

3.  Synthetic peptides from a conserved region of gp120 induce broadly reactive anti-HIV responses.

Authors:  W J Morrow; W M Williams; A S Whalley; T Ryskamp; R Newman; C Y Kang; S Chamat; H Köhler; T Kieber-Emmons
Journal:  Immunology       Date:  1992-04       Impact factor: 7.397

4.  Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines.

Authors:  John R Mascola; Patricia D'Souza; Peter Gilbert; Beatrice H Hahn; Nancy L Haigwood; Lynn Morris; Christos J Petropoulos; Victoria R Polonis; Marcella Sarzotti; David C Montefiori
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

5.  Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus.

Authors:  R E Means; T Greenough; R C Desrosiers
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

6.  Challenge of chimpanzees (Pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp120.

Authors:  L O Arthur; J W Bess; D J Waters; S W Pyle; J C Kelliher; P L Nara; K Krohn; W G Robey; A J Langlois; R C Gallo
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

7.  An intronic G run within HIV-1 intron 2 is critical for splicing regulation of vif mRNA.

Authors:  Marek Widera; Steffen Erkelenz; Frank Hillebrand; Aikaterini Krikoni; Darius Widera; Wolfgang Kaisers; René Deenen; Michael Gombert; Rafael Dellen; Tanya Pfeiffer; Barbara Kaltschmidt; Carsten Münk; Valerie Bosch; Karl Köhrer; Heiner Schaal
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

8.  The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope.

Authors:  C Wilson; M S Reitz; K Aldrich; P J Klasse; J Blomberg; R C Gallo; M Robert-Guroff
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

9.  Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.

Authors:  Guangshun Wang; Karen M Watson; Alan Peterkofsky; Robert W Buckheit
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

10.  Mutations in the principal neutralization determinant of human immunodeficiency virus type 1 affect syncytium formation, virus infectivity, growth kinetics, and neutralization.

Authors:  R J Grimaila; B A Fuller; P D Rennert; M B Nelson; M L Hammarskjöld; B Potts; M Murray; S D Putney; G Gray
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.